文献速递骨软组织肉瘤与黑色素瘤

纳武利尤单抗联合瑞拉利单抗治疗抗PD-(L)1治疗后进展的晚期黑色素瘤:I/IIa期RELATIVITY-020试验结果

Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial.
PubMed 文献 · J Clin Oncol · 2023-02-13

RELATIVITY-020试验D部分评估纳武利尤单抗联合瑞拉利单抗在抗PD-(L)1治疗后进展的晚期黑色素瘤中的疗效与安全性。518例患者(D1=354,D2=164)接受治疗,客观缓解率D1为12.0%、D2为9.2%,安全性可控,部分患者获得持久临床获益。

要点

  • D1组客观缓解率12.0%(95%CI 8.8-15.8),D2组9.2%(95%CI 5.2-14.7)。
  • D1组中位PFS 2.1个月,D2组3.2个月;6个月PFS率分别为29.1%和27.7%。
  • 3-4级治疗相关不良事件发生率D1为15.0%、D2为12.8%,发生1例3级心肌炎,无治疗相关死亡。

核心结论

  • 纳武利尤单抗联合瑞拉利单抗在抗PD-(L)1治疗后进展的重度经治晚期黑色素瘤患者中安全性可控,并在部分患者中显示出持久的临床活性。

研究设计与样本

  • I/IIa期、开放标签RELATIVITY-020试验D部分,评估纳武利尤单抗联合瑞拉利单抗在晚期黑色素瘤中的疗效与安全性。
  • 纳入在1种(D1)或≥1种(D2)含抗PD-(L)1方案治疗期间或治疗结束后3个月内进展的晚期黑色素瘤患者。
  • 共518例患者接受纳武利尤单抗联合瑞拉利单抗治疗(D1=354例;D2=164例)。
  • 安全性为主要终点;客观缓解率(共同主要终点)和PFS由盲法独立中心审查(BICR)评估。

主要发现

  • 可评估患者中,BICR评估的客观缓解率D1组为12.0%(95%CI 8.8-15.8,n=351),D2组为9.2%(95%CI 5.2-14.7,n=163)。
  • 缓解似乎富集于肿瘤表达PD-L1或LAG-3的患者,但无论PD-L1和LAG-3表达如何(1%)均观察到缓解。
  • 中位缓解持续时间D1组未达到(95%CI 12.9-未达到),D2组为12.8个月(95%CI 6.9-12.9)。
  • BICR评估的中位PFS D1组为2.1个月(95%CI 1.9-3.5),D2组为3.2个月(95%CI 1.9-3.6)。
  • 6个月PFS率D1组为29.1%(95%CI 24.2-34.1),D2组为27.7%(95%CI 20.5-35.4)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Nivolumab and relatlimab activity in advanced melanoma with prior progression on anti-programmed death-1/programmed death ligand 1 (PD-(L)1)-containing regimens is under investigation. RELATIVITY-047 demonstrated significantly improved progression-free survival (PFS) for nivolumab and relatlimab over nivolumab in previously untreated advanced melanoma. METHODS: The phase I/IIa, open-label RELATIVITY-020 trial part D assessed efficacy and safety of nivolumab and relatlimab in advanced melanoma with progression during, or within 3 months of, 1 (D1) or ≥ 1 (D2) anti-PD-(L)1-containing regimens. Safety was a primary end point. Objective response rate (coprimary end point) and PFS by blinded independent central review (BICR) were assessed. RESULTS: Five hundred eighteen patients (D1 = 354; D2 = 164) received nivolumab and relatlimab. Among evaluable patients, the objective response rate by BICR was 12.0% (95% CI, 8.8 to 15.8) in D1 (n = 351) and 9.2% (95% CI, 5.2 to 14.7) in D2 (n = 163). Responses appeared to be enriched among patients with tumors expressing programmed death ligand 1 or lymphocyte activation gene 3; however, responses were observed regardless of programmed death ligand 1 and lymphocyte activation gene 3 expression (1%). The median duration of response was not reached (95% CI, 12.9 to not reached) in D1 and 12.8 months (95% CI, 6.9 to 12.9) in D2. The median PFS by BICR was 2.1 months (95% CI, 1.9 to 3.5) in D1 and 3.2 months (95% CI, 1.9 to 3.6) in D2; the 6-month PFS rate was 29.1% (95% CI, 24.2 to 34.1) and 27.7% (95% CI, 20.5 to 35.4), respectively. The grade 3-4 treatment-related adverse event incidence was 15.0% in D1 and 12.8% in D2. One case of grade 3 myocarditis and no treatment-related deaths occurred across part D. CONCLUSION: Nivolumab and relatlimab had a manageable safety profile and demonstrated durable clinical activity in a proportion of patients with heavily pretreated advanced melanoma with prior progression on anti-PD-(L)1-containing regimens. UNLABELLED: [Media: see text].

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Ascierto PA, Lipson EJ, Dummer R, et al. Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial. J Clin Oncol. 2023. PMID: 36780608. doi:10.1200/JCO.22.02072

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。